HOOKIPA Pharma To Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is set to release its fourth quarter and full year 2020 financial results on March 18, 2021, before market opens. A live conference call will follow at 8:30 am EDT to discuss the results and provide a corporate update. HOOKIPA is focused on developing immunotherapeutics using its proprietary arenavirus platform, with candidates HB-201 and HB-202 in a Phase 1/2 trial for HPV 16-positive cancers, and HB-101 in a Phase 2 trial for CMV vaccination in kidney transplant patients. The company has also partnered with Gilead Sciences for HIV and hepatitis B research.
- Scheduled release of Q4 and full year 2020 financial results on March 18, 2021.
- Live conference call to discuss financial results and corporate updates allows investor engagement.
- Ongoing clinical trials for HB-201, HB-202, and HB-101 show active development in oncology and infectious diseases.
- Collaboration with Gilead Sciences expands the company's research portfolio in significant disease areas.
- None.
NEW YORK and VIENNA, Austria, March 09, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2020 financial results before the market opens on Thursday, March 18, 2021. Following the release, the Company will host a live conference call and webcast at 8:30 am EDT to discuss its financial results and corporate update.
To access the live conference call, please register here. A live audio webcast of the event will also be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.
HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. Our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.
HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.
HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic hepatitis B infections.
Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
| Media | Investors |
| Nina Waibel | Matt Beck |
| Senior Director - Communications | Executive Director - Investor Relations |
| nina.waibel@hookipapharma.com | matthew.beck@hookipapharma.com |
FAQ
When will HOOKIPA Pharma release its financial results for Q4 2020?
What are the key products in HOOKIPA Pharma's pipeline?
What time is the conference call for HOOKIPA's financial results?
Who is HOOKIPA partnering with for HIV and hepatitis B research?
